MedicaState, the nation's sole public healthcare operator, wields excessive buyer power. It exploits its dominant market position to squeeze specialized medical tech startups and equipment suppliers, forcing down the procurement prices it pays for orthopedic implants and surgical devices. If a supplier protests or attempts to negotiate, MedicaState retaliates by delaying clinical trial approvals, reducing hospital order volumes, or fast-tracking its own in-house alternative designs instead.
Evaluate the likely economic costs of a monopsony operating in a market such as healthcare procurement.
